All News

2068 articles, sorted by publication time.

Biopharma · us

RAS-targeted race in pancreatic cancer reaches a key readout as daraxonrasib pushes the survival threshold forward

Revolution Medicines’ oral RAS(ON) inhibitor has reported overall survival data superior to chemotherapy in a Phase 3 trial, offering a rare clinical bright spot for metastatic pancreatic cancer; but with details limited by disclosure from a single news source, the magnitude of benefit, population stratification, and regulatory interpretation remain the next areas of focus.